Semaglutide Dosage

In clinical trials and on its product label, semaglutide is given as a once-weekly subcutaneous injection whose dose is raised gradually over about the first sixteen weeks before a maintenance level is held. The well-documented weight-management schedule steps up every four weeks — 0.25 mg, then 0.5 mg, 1.0 mg, 1.7 mg and finally 2.4 mg once weekly — and that top dose is what the large STEP obesity programme (Wilding et al., NEJM 2021) studied. The lower diabetes range that peaks around 1.0 mg or 2.0 mg follows the same slow-start logic. That published titration is the whole of what the dosing evidence describes.

There is no validated consumer or at-home semaglutide protocol. The figures below are trial-design and label parameters, reported here as research convention — not a personal dose, not a treatment plan, and not a recommendation to use any amount. This page answers the informational question, namely how semaglutide is dosed and escalated, and is deliberately separate from the shop listings, which exist only to specify and supply the research compound. To see stocked formats and strengths, start at the semaglutide category hub; to understand the dosing evidence, read on.

How semaglutide was dosed in trials and on the label

Semaglutide is a GLP-1 receptor agonist — a single molecule that mimics the gut hormone GLP-1 — and across its published work it is administered once weekly by subcutaneous injection. The defining feature of the dosing design is not the route but the gradual escalation: no one begins at the maintenance dose. Treatment opens at a very low weekly dose and is increased in fixed steps, so the body meets the compound slowly.

In the STEP 1 obesity trial, adults were randomised to placebo or to once-weekly semaglutide titrated to a 2.4 mg maintenance dose, reached through a sixteen-week escalation and then held across a sixty-eight-week study. The same 0.25-to-2.4 mg step pattern is set out on the weight-management product label. The trial reported a mean body-weight change of about −15% at sixty-eight weeks in the semaglutide group versus roughly −2% on placebo; those figures describe the study population as a whole and are not a result any individual should expect, nor a reason to target a particular dose.

The label dose-escalation schedule

The table shows the standard weight-management escalation to the 2.4 mg maintenance tier, taken from the STEP trial design and the product label. Each step lasts about four weeks. Treat the week boundaries as approximate — a step can be extended if a level is not yet tolerated. These are label and trial figures, not a recommended personal dose.

Treatment period	Weekly subcutaneous dose	Purpose
Weeks 1–4	0.25 mg (starting dose)	Introduce the compound at the lowest step
Weeks 5–8	0.5 mg	First escalation
Weeks 9–12	1.0 mg	Second escalation
Weeks 13–16	1.7 mg	Third escalation
Week 17 onward	2.4 mg (maintenance)	Held as the maintenance dose

The 0.25 mg starting dose is a titration step to help the body adjust, not itself a therapeutic dose. Lower-target schedules — for example the diabetes range — simply stop climbing sooner, levelling off at a maintenance dose below 2.4 mg once weekly. The principle is the same in every case: start low, step up on a fixed cadence, then hold.

Why the dose is escalated: GI tolerability

The reason for stepping up slowly is gastrointestinal tolerability. Like other GLP-1 agonists, semaglutide's most commonly reported adverse events are gastrointestinal — nausea, diarrhoea, vomiting and constipation — and these appear most often when starting the compound and just after each dose increase. Escalation exists to give that tolerance time to build. If a step is not comfortable, the published guidance is to hold at the current dose for another interval rather than push higher, and most reported events are mild to moderate and tend to settle as the body adjusts. For the fuller safety picture, see semaglutide side effects.

Reconstitution and draw volume

Semaglutide supplied as a lyophilised (freeze-dried) vial is a powder, not a ready-to-use liquid, so it must be reconstituted with bacteriostatic water before any volume can be drawn. The concept is simple, but the arithmetic is where mistakes happen: the amount of water you add sets the concentration, and the concentration decides how many units on the syringe correspond to a given milligram figure. Add more water and each unit carries less peptide; add less and each unit carries more.

Do the maths before you touch the vial. Our peptide reconstitution calculator is the core companion to this guide: enter the vial strength, the water volume and your target amount, and it returns the draw volume on a standard insulin syringe. Use it for the HD Labs Semaglutide 10 vial so the concentration you prepare matches the schedule you are studying. We give the concept here, not a personal dose — what you draw is a decision for a qualified professional, not for this page.

Storage

Semaglutide is temperature-sensitive. As a general handling matter, the lyophilised powder is kept refrigerated at about 2–8 °C and protected from light and freezing; once reconstituted, the solution is also refrigerated and used within a limited window rather than stored indefinitely. BeSkinny ships temperature-sensitive peptides cold-chain with gel packs to preserve integrity in transit across South Africa. Always defer to the certificate of analysis and any handling notes supplied with your specific batch, which take precedence over general guidance.

What affects tolerability

Several factors shape how the reported tolerability pattern plays out in the trial data:

• Starting low. The 0.25 mg opening step is a deliberately sub-therapeutic dose whose only job is to ease the body into the compound before any effective level.
• Speed of escalation. Longer intervals between steps give tolerance more time to develop; the label steps up roughly every four weeks and allows a step to be extended.
• Maintenance tier. Higher weekly targets carry a heavier burden of the same class effects, so the 2.4 mg tier sits at the top of both the efficacy and the side-effect range.
• Individual variation. Trial averages hide wide person-to-person differences; group data cannot predict any individual response.

Because these factors interact, the escalation schedule is best read as a tolerability tool from the trial and label design rather than a number to copy. For the broader safety picture across peptides, see are peptides safe?, and for how the single GLP-1 agonist compares with the dual agonist, see tirzepatide vs semaglutide.

Research-use and medical disclaimer

Everything on this page is provided strictly for laboratory and research reference. It is not medical advice, not dosing advice, and not a human dosing protocol. The doses, escalation steps and outcome figures describe what published clinical trials and the manufacturer's product label report, cited following standard research-reference convention; they are not instructions, and they are not a validated consumer protocol, which does not exist. BeSkinny supplies semaglutide as a research compound only. Before making any decision about a GLP-1 agonist, consult a registered healthcare professional who can account for your individual circumstances. Nothing here replaces that conversation.

Frequently asked questions

How much semaglutide is used per week?

Semaglutide is dosed once weekly. In the weight-management schedule the dose is titrated from 0.25 mg up to a 2.4 mg maintenance dose over about sixteen weeks; lower diabetes-range schedules level off sooner. These are trial and label figures, not a recommended personal dose — what is appropriate for any individual is a question for a qualified healthcare professional.

How do you reconstitute semaglutide?

A lyophilised vial is a freeze-dried powder that must be dissolved in bacteriostatic water before any dose can be drawn. The water volume you add sets the concentration and therefore the number of syringe units per milligram. Work the numbers out first with the peptide reconstitution calculator; this page explains the concept, not a personal dose.

Why start at 0.25 mg?

To manage gastrointestinal tolerability. Nausea, diarrhoea, vomiting and constipation are the most commonly reported events and are most frequent when starting and just after each step-up. The 0.25 mg dose is a titration step, not a therapeutic level: starting this low and stepping up gives tolerance time to build before an effective dose is reached.

How long does it take to reach 2.4 mg?

On the standard weight-management schedule, about sixteen weeks — four four-week steps (0.25, 0.5, 1.0 and 1.7 mg) before the 2.4 mg maintenance dose from week seventeen. A step can be extended by a further four weeks if a level is not tolerated, so an individual's timeline can be longer.

Is there an approved consumer dose?

The dosing figures that exist are trial-design and product-label parameters like those above; there is no validated at-home research protocol. Any real-world decision about a GLP-1 agonist belongs with a registered healthcare professional, not with a web page. BeSkinny supplies semaglutide as a research compound only.

Sources

• Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002. NEJM and PubMed
• Wegovy (semaglutide) injection — Prescribing Information (dosing and dose escalation), Drugs@FDA. U.S. Food and Drug Administration. accessdata.fda.gov
• Semaglutide (Wegovy) — label and dosing record, DailyMed. U.S. National Library of Medicine. dailymed.nlm.nih.gov
• Drugs.com. Semaglutide — uses, dosage, side effects. drugs.com